vrc07-523ls
mAbexperimental
Clinical trial activity
21 trials · 29 clinical orgs · 0 marketing orgs
Phase 1
17
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Oct 23, 2017 (NCT03205917)
Timeline
Indications
Mechanism of action
- T-cell surface antigen CD4INHIBITOR
CD4 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594510 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06987318 | Phase 1 | Feb 15, 2026 | Monogram Biosciences, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT06484335 | Phase 1 | Feb 1, 2025 | Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Army |
| NCT06812494 | Phase 2 | Feb 1, 2025 | Department of Health and Human Services, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT06517693 | Phase 1 | Nov 1, 2024 | National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Mental Health (NIMH), National Institutes of Health (NIH), University of California, Irvine |
| NCT06508749 | Phase 1/Phase 2 (Phase 2) | Oct 17, 2024 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05719441 | Phase 2 | Feb 1, 2024 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05890963 | Phase 1 | Nov 28, 2023 | Columbia University, Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Army |
| NCT05769569 | Phase 1 | Sep 1, 2023 | Chulalongkorn University, Henry M. Jackson Foundation for the Advancement of Military Medicine, Janssen Pharmaceutica NV, United States Army |
| NCT05281510 | Phase 2 | Jun 9, 2022 | Gilead Sciences |
| NCT05184452 | Phase 1 | Nov 15, 2021 | Centre for the AIDS Programme of Research in South Africa, Department of Health and Human Services, Emory University, George Washington University, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT04983030 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2021 | Harvard University, Janssen Pharmaceutica NV, National Institute of Allergy and Infectious Diseases (NIAID), Orlando Immunology Center, University of Texas at Houston |
| NCT04340596 | Phase 1 | Jul 1, 2020 | Cornell University, ImmunityBio, Inc., National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University |
| NCT04212091 | Phase 1 | Feb 10, 2020 | Emory University, Harvard University, HIV Prevention Trials Network, HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), University of North Carolina at Chapel Hill |
| NCT03928821 | Phase 1 | Jun 30, 2019 | Columbia University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03739996 | Phase 2 | Jun 30, 2019 | Cornell University, National Institute of Allergy and Infectious Diseases (NIAID), Northwestern University, University of Pennsylvania |
| NCT03803605 | Phase 1 | Feb 12, 2019 | National Institute of Allergy and Infectious Diseases (NIAID), University of North Carolina at Chapel Hill |
| NCT03735849 | Phase 1 | Jan 18, 2019 | Harvard University, National Institute of Allergy and Infectious Diseases (NIAID), University of Washington |
| NCT03721510 | Phase 1/Phase 2 (Phase 2) | Dec 3, 2018 | Harvard University, International AIDS Vaccine Initiative, National Institute of Allergy and Infectious Diseases (NIAID), Orlando Immunology Center |
| NCT03565315 | Phase 1 | Jul 10, 2018 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03387150 | Phase 1 | Feb 2, 2018 | Harvard University, National Institute of Allergy and Infectious Diseases (NIAID), University of North Carolina at Chapel Hill |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (29)
29 organizations
Page 1 / 2